Tag
Drug Metabolism
84 genetic variants with this tag.
| RSID | Gene | Description | Category | ||
|---|---|---|---|---|---|
| rs1042713 | ADRB2 Arg16Gly | Beta-2 adrenergic receptor variant affecting receptor downregulation, exercis... | Fitness & Body | Strong | |
| rs10509679 | CYP2C9 | Intronic CYP2C9 haplotype tag associated with increased ischemic stroke risk ... | Coronary Artery Disease & Atherosclerosis | Emerging | |
| rs10305492 | GLP1R A316T | Rare protective missense variant in the GLP-1 receptor associated with lower ... | Pharmacogenomics | Strong | |
| rs10403955 | CYP2B6 | Intronic CYP2B6 haplotype-tagging variant associated with altered plasma conc... | Pharmacogenomics | Moderate | |
| rs11854484 | SLC28A2 SLC28A2 Pro22Leu | Missense variant in the concentrative nucleoside transporter 2 (CNT2) gene th... | Vitamins & Nutrient Absorption | Moderate | |
| rs2032582 | ABCB1 G2677T/A (Ser893Ala/Thr) | Triallelic missense variant in the P-glycoprotein efflux pump that reduces th... | Gamete Quality & DNA Repair | Moderate | |
| rs1045642 | ABCB1 C3435T | Synonymous variant in P-glycoprotein affecting drug efflux pump expression an... | Pharmacogenomics | Moderate | |
| rs1057910 | CYP2C9 *3 | No-function CYP2C9 variant with major warfarin implications | Pharmacogenomics | Established | |
| rs2968864 | KCNH2 KCNH2 QT interval GWAS variant (7q36.1) | Intergenic variant at 7q36.1 near KCNH2 (hERG potassium channel) that modulat... | Arrhythmia & Heart Rhythm | Strong | |
| rs1058932 | CYP2C8 | CYP2C8 3-prime UTR variant associated with cardiovascular risk via altered ep... | Pharmacogenomics | Moderate | |
| rs1065852 | CYP2D6 *10 | Decreased function CYP2D6 variant common in Asian populations | Pharmacogenomics | Established | |
| rs1142345 | TPMT *3C | No-function variant causing deficient thiopurine methylation; most common TPM... | Pharmacogenomics | Established | |
| rs1800629 | TNF -308 G>A | Promoter variant increasing TNF-alpha production approximately 2-fold, associ... | TNF, NF-kB & Inflammatory Cytokines | Strong | |
| rs116855232 | NUDT15 Arg139Cys | Nucleotide diphosphatase that inactivates toxic thiopurine metabolites; reduc... | Pharmacogenomics | Established | |
| rs12248560 | CYP2C19 *17 | Increased function CYP2C19 variant - rapid/ultrarapid metabolizer | Pharmacogenomics | Established | |
| rs6742078 | UGT1A10 | Intronic variant in the UGT1A gene cluster (chromosome 2q37) strongly associa... | Uric Acid & Kidney Function | Strong | |
| rs12980275 | IFNL3 | Downstream variant near IFNL3 — third IL28B locus predictor of hepatitis C sp... | Pharmacogenomics | Established | |
| rs1341162 | CYP2C8 | Intronic CYP2C8 haplotype-tagging variant linked to bisphosphonate-related os... | Pharmacogenomics | Moderate | |
| rs72551348 | UGT1A1 Q331R | Rare pathogenic missense variant in the UGT1A1 gene that severely reduces bil... | Uric Acid & Kidney Function | Strong | |
| rs1208 | NAT2 R268K | NAT2 acetylation speed tag SNP - marks rapid vs slow acetylator haplotypes | Methylation & Detox | Established | |
| rs1341164 | CYP2C8 | Intronic CYP2C8 variant tagging a haplotype associated with altered taxane dr... | Pharmacogenomics | Emerging | |
| rs12044852 | CD58 | Intronic CD58 variant in strong LD with rs2300747 (r²=0.929); the C allele dr... | Neurology & Cognition | Strong | |
| rs16947 | CYP2D6 *2 | Common CYP2D6 variant defining the *2 allele; previously considered normal-fu... | Pharmacogenomics | Strong | |
| rs2231137 | ABCG2 ABCG2 V12M (Val12Met) | Missense variant in the ABCG2 transporter that impairs membrane localization ... | Coronary Artery Disease & Atherosclerosis | Moderate | |
| rs33980500 | TRAF3IP2 D10N | Missense variant in Act1 that abolishes IL-17 signaling by disrupting TRAF6 b... | Psoriasis & Spondyloarthropathy | Strong | |
| rs17002852 | CYP2D6 | Synonymous CYP2D6 variant that causes allele dropout in standard CYP2D6*3 gen... | Pharmacogenomics | Moderate | |
| rs1799853 | CYP2C9 *2 | Decreased function variant affecting warfarin, phenytoin, and NSAIDs | Pharmacogenomics | Established | |
| rs2066853 | AHR Arg554Lys | Aryl hydrocarbon receptor variant in the transactivation domain that alters A... | Hormones & Sleep | Moderate | |
| rs1799971 | OPRM1 A118G | Mu-opioid receptor variant affecting opioid response and pain sensitivity | Pharmacogenomics | Strong | |
| rs1799930 | NAT2 R197Q | Slow acetylator variant affecting Phase II detoxification capacity | Methylation & Detox | Established | |
| rs1800460 | TPMT *3B | Decreased-function variant causing reduced thiopurine methylation; pairs with... | Pharmacogenomics | Established | |
| rs1934951 | CYP2C8 | Intronic CYP2C8 variant associated with paclitaxel-induced toxicity and bisph... | Pharmacogenomics | Moderate | |
| rs7594951 | SRD5A2 SRD5A2 intron 4 regulatory variant | Deep intronic variant in the testosterone-to-DHT converting enzyme; the minor... | Reproductive Hormones | Emerging | |
| rs1934953 | CYP2C8 | Intronic CYP2C8 variant linked to hypertension susceptibility, COPD risk, and... | Pharmacogenomics | Emerging | |
| rs5186 | AGTR1 A1166C | 3' UTR variant in angiotensin II type 1 receptor affecting blood pressure reg... | Blood Pressure & Hypertension | Moderate | |
| rs887829 | UGT1A1 UGT1A1*80 | Promoter variant in UGT1A1 that tags the *28 reduced-expression haplotype; T ... | Vascular Inflammation & Remodeling | Strong | |
| rs1934963 | CYP2C9 | Deep intronic CYP2C9 variant associated with altered drug response | Pharmacogenomics | Emerging | |
| rs1934967 | CYP2C9 | Intronic CYP2C9 haplotype tag associated with altered warfarin sensitivity an... | Pharmacogenomics | Moderate | |
| rs1934980 | CYP2C8 | Intronic CYP2C8 variant associated with bisphosphonate-related jaw complicati... | Pharmacogenomics | Moderate | |
| rs1801280 | NAT2 I114T | Phase II detoxification - acetylation of aromatic amines and certain medications | Methylation & Detox | Established | |
| rs2031920 | CYP2E1 *5B (RsaI) | Promoter variant increasing CYP2E1 inducibility, elevating oxidative stress f... | Pharmacogenomics | Moderate | |
| rs2069526 | CYP1A2 -739T>G | Intronic CYP1A2 variant near the 5' end; G allele is associated with altered ... | Pharmacogenomics | Emerging | |
| rs6311 | HTR2A -1438G>A | Regulatory variant in serotonin 2A receptor gene affecting SSRI side effects ... | Mood & Behavior | Moderate | |
| rs2108622 | CYP4F2 V433M (*3) | Reduces vitamin K metabolism, requiring higher warfarin doses to achieve anti... | Pharmacogenomics | Established | |
| rs2231142 | ABCG2 Q141K | Reduces ABCG2 transporter function affecting rosuvastatin levels and uric aci... | Pharmacogenomics | Established | |
| rs2246709 | CYP3A4 | Intronic CYP3A4 variant associated with altered drug clearance, affecting met... | Pharmacogenomics | Moderate | |
| rs4410790 | AHR | Regulatory variant 54 kb upstream of the aryl hydrocarbon receptor gene; the ... | Hormones & Sleep | Strong | |
| rs2289669 | SLC47A1 MATE1 G-1853A | Intronic variant in MATE1, the renal and hepatic metformin efflux transporter... | Pharmacogenomics | Moderate | |
| rs2480256 | CYP2E1 | 3' UTR variant that increases CYP2E1 expression, raising hepatotoxicity risk ... | Pharmacogenomics | Moderate | |
| rs2515641 | CYP2E1 | Synonymous exon-8 variant that reduces CYP2E1 mRNA and protein expression, al... | Pharmacogenomics | Moderate | |
| rs2740574 | CYP3A4 *1B -392A>G | Promoter variant affecting CYP3A4 expression, most common in African populations | Pharmacogenomics | Moderate | |
| rs28371706 | CYP2D6 *17 | Decreased-function CYP2D6 allele common in African populations, reducing meta... | Pharmacogenomics | Established | |
| rs28371725 | CYP2D6 *41 | Intronic splice variant causing decreased CYP2D6 enzyme activity through aber... | Pharmacogenomics | Established | |
| rs28399433 | CYP2A6 *9 (TATA box) | Promoter variant that reduces CYP2A6 expression by ~50%, slowing nicotine met... | Pharmacogenomics | Strong | |
| rs316019 | SLC22A2 Ala270Ser | Reduces OCT2 organic cation transporter function in the kidney, lowering metf... | Pharmacogenomics | Moderate | |
| rs35599367 | CYP3A4 *22 | Intronic splice variant causing ~50% reduced CYP3A4 mRNA expression, affectin... | Pharmacogenomics | Established | |
| rs5030868 | G6PD G6PD Mediterranean | Severe Class II G6PD deficiency variant (c.563C>T, p.Ser188Phe) causing less ... | Blood Sugar & Diabetes | Established | |
| rs373489637 | CYP2B6 V183G | Near-complete loss-of-function CYP2B6 variant causing severely impaired metab... | Pharmacogenomics | Moderate | |
| rs3745274 | CYP2B6 516G>T | Decreased-function variant affecting metabolism of efavirenz, methadone, bupr... | Pharmacogenomics | Established | |
| rs3791033 | KDM4A | Intronic variant in KDM4A histone demethylase associated with problematic opi... | Pharmacogenomics | Moderate | |
| rs3814637 | CYP2C19 | Upstream CYP2C19 variant associated with altered R-warfarin clearance | Pharmacogenomics | Moderate | |
| rs3918290 | DPYD *2A | Most critical pharmacogenomic variant causing complete loss of DPD enzyme fun... | Pharmacogenomics | Established | |
| rs4148323 | UGT1A1 *6 Gly71Arg | Phase II glucuronidation enzyme that metabolizes bilirubin and many drugs inc... | Pharmacogenomics | Established | |
| rs4149056 | SLCO1B1 *5 | Statin transport - affects muscle side effect risk with statins | Pharmacogenomics | Established | |
| rs4244285 | CYP2C19 *2 | No-function CYP2C19 variant affecting PPIs, clopidogrel, and some antidepress... | Pharmacogenomics | Established | |
| rs76723693 | G6PD G6PD Nefza (c.968T>C) | Missense variant in glucose-6-phosphate dehydrogenase causing Class III G6PD ... | Blood Sugar & Diabetes | Strong | |
| rs4986893 | CYP2C19 *3 | No-function CYP2C19 stop-gain variant — second most common loss-of-function a... | Pharmacogenomics | Established | |
| rs55785340 | CYP3A4 *2 | Missense variant reducing CYP3A4-mediated nifedipine clearance, causing eleva... | Pharmacogenomics | Moderate | |
| rs55886062 | DPYD *13 | No-function DPYD star allele (I560S) causing severe DPD deficiency; one of fo... | Pharmacogenomics | Established | |
| rs55897648 | CYP2E1 *3 (Val389Ile) | CYP2E1*3 missense variant with no demonstrated change in enzyme activity | Pharmacogenomics | Emerging | |
| rs56038477 | DPYD HapB3 tag (c.1236G>A, E412E) | Synonymous exon-11 tag SNP for the DPYD HapB3 haplotype; benign on its own bu... | Pharmacogenomics | Established | |
| rs622342 | SLC22A1 A>C | Intronic variant in the OCT1 organic cation transporter reducing hepatic metf... | Pharmacogenomics | Moderate | |
| rs6413419 | CYP2E1 *4 (V179I) | Missense variant (Val179Ile) defining the CYP2E1*4 allele | Pharmacogenomics | Emerging | |
| rs671 | ALDH2 *2 | Alcohol metabolism - flush reaction and cancer risk | Pharmacogenomics | Established | |
| rs67784355 | CYP3A4 *11 (Thr363Met) | Rare missense variant in CYP3A4 that reduces protein expression and enzymatic... | Pharmacogenomics | Emerging | |
| rs71328650 | CYP2D6 | Intronic CYP2D6 haplotype tag variant (rs28371702 canonical form) associated ... | Pharmacogenomics | Emerging | |
| rs72547515 | CYP1A2 *16 (Arg377Gln) | Nearly-inactive CYP1A2 missense variant — carriers have severely impaired met... | Pharmacogenomics | Moderate | |
| rs72547516 | CYP1A2 Ile386Val | Rare CYP1A2 missense variant (Ile386Val) associated with potentially reduced ... | Pharmacogenomics | Emerging | |
| rs72547517 | CYP1A2 *8 | CYP1A2*8 — near-complete loss-of-function missense variant causing severely r... | Pharmacogenomics | Strong | |
| rs762551 | CYP1A2 *1F | CYP1A2 *1F intronic inducibility variant — defines fast vs slow caffeine meta... | Pharmacogenomics | Strong | |
| rs776746 | CYP3A5 *3 | Splice site variant creating a non-functional CYP3A5 enzyme, dramatically aff... | Pharmacogenomics | Established | |
| rs8099917 | IFNL3 | Intergenic variant upstream of IFNL3 — second major IL28B locus predictor of ... | Pharmacogenomics | Established | |
| rs8192780 | CYP2E1 | Downstream regulatory variant near CYP2E1 associated with nasopharyngeal carc... | Pharmacogenomics | Emerging | |
| rs9923231 | VKORC1 -1639G>A | Warfarin sensitivity - determines initial dosing | Pharmacogenomics | Established |